nach oben

Cardiovascular Intervention and Therapeutics

Erschienen in:

05.01.2024 | Invited Review Article

Diagnosis and treatment of cardiovascular disease in patients with heritable connective tissue disorders or heritable thoracic aortic diseases

verfasst von: Takeshi Yagyu, Teruo Noguchi

Erschienen in: Cardiovascular Intervention and Therapeutics | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Patients with heritable connective tissue disorders (HCTDs), represented by Marfan syndrome, can develop fatal aortic and/or arterial complications before age 50. Therefore, accurate diagnosis, appropriate medical treatment, and early prophylactic surgical treatment of aortic and arterial lesions are essential to improve prognosis. Patients with HCTDs generally present with specific physical features due to connective tissue abnormalities, while some patients with heritable thoracic aortic diseases (HTADs) have few distinctive physical characteristics. The development of genetic testing has made it possible to provide accurate diagnoses for patients with HCTDs/HTADs. This review provides an overview of the diagnosis and treatment of HCTDs/HTADs, including current evidence on cardiovascular interventions for this population.

Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH, et al. Marfan syndrome. Nat Rev Dis Prim. 2021;7:64.PubMedCrossRef

Chiu HH, Wu MH, Chen HC, Kao FY, Huang SK. Epidemiological profile of Marfan syndrome in a general population: a national database study. Mayo Clin Proc. 2014;89:34–42.PubMedCrossRef

Groth KA, Hove H, Kyhl K, Folkestad L, Gaustadnes M, Vejlstrup N, et al. Prevalence, incidence, and age at diagnosis in Marfan syndrome rare systemic diseases. Orphanet J Rare Dis. 2015;10:1–10.CrossRef

Dietz HC, Cutting CR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337–9.ADSPubMedCrossRef

Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De BJ, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47:476–85.PubMedCrossRef

Arnaud P, Milleron O, Hanna N, Ropers J, Ould Ouali N, Affoune A, et al. Clinical relevance of genotype–phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. Genet Med. 2021;23:1296–304.PubMedPubMedCentralCrossRef

Murdoch JL, Walker BA, Halpern BL, Kuzma JW, Mckusick VA. Life expectancy and causes of death in the Marfan syndrome. N Engl J Med. 1972;286:804–8.PubMedCrossRef

Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75:157–60.PubMedCrossRef

Gray J, Bridges A, West R, McLeish L, Stuart A, Dean J, et al. Life expectancy in British Marfan syndrome populations. Clin Genet. 1998;54:124–8.PubMedCrossRef

10.

Shores J. Progression of aortic dilatation and the benefit of long-term beta adrenergic blockade in Marfan’s syndrome. N Engl J Med. 1994;330:1335–41.PubMedCrossRef

11.

Groenink M, Den Hartog AW, Franken R, Radonic T, De Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34:3491–500.PubMedCrossRef

12.

Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med. 2014;371:2061–71.PubMedPubMedCentralCrossRef

13.

Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015;36:2160–6.PubMedCrossRef

14.

Forteza A, Evangelista A, Sánchez V, Teixidó-Turà G, Sanz P, Gutiérrez L, et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Eur Heart J. 2016;37:978–85.PubMedCrossRef

15.

Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA, et al. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet. 2019;394:2263–70.PubMedPubMedCentralCrossRef

16.

Byers PH. Determination of the molecular basis of Marfan syndrome: a growth industry. J Clin Invest. 2004;114:161–3.ADSPubMedPubMedCentralCrossRef

17.

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117–21.ADSPubMedPubMedCentralCrossRef

18.

Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L, et al. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet. 2022;400:822–31.PubMedPubMedCentralCrossRef

19.

Yagyu T, Noguchi T, Asano Y, Ida K, Ogata S, Nishimura K, et al. Association between genetic diagnosis and clinical outcomes in patients with heritable thoracic aortic disease. J Am Heart Assoc. 2023;12: e028625.PubMedPubMedCentralCrossRef

20.

Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004;36:855–60.PubMedPubMedCentralCrossRef

21.

Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275–81.PubMedCrossRef

22.

Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355:788–98.PubMedCrossRef

23.

Attias D, Stheneur C, Roy C, Collod-Béroud G, Detaint D, Faivre L, et al. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation. 2009;120:2541–9.PubMedCrossRef

24.

van de Laar IM, Oldenburg RA, Pals G, Roos-hesselink JW, de Graaf BM, Verhagen JM, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011;43:121–8.PubMedCrossRef

25.

Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-bober J, et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet. 2012;44:922–7.PubMedPubMedCentralCrossRef

26.

Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, et al. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 2012;44:916–21.PubMedPubMedCentralCrossRef

27.

Rienhoff HY, Yeo CY, Morissette R, Khrebtukova I, Melnick J, Luo S, et al. A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys–Dietz syndrome. Am J Med Genet Part A. 2013;161:2040–6.CrossRef

28.

van der Linde D, van de Laar IM, Bertoli-Avella AM, Oldenburg RA, Bekkers JA, Mattace-Raso FU, et al. Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am Coll Cardiol. 2012;60:397–403.PubMedCrossRef

29.

MacCarrick G, Black JH, Bowdin S, El-Hamamsy I, Frischmeyer-Guerrerio PA, Guerrerio AL, et al. Loeys–Dietz syndrome: a primer for diagnosis and management. Genet Med. 2014;16:576–87.PubMedPubMedCentralCrossRef

30.

Teixidó-tura G, Franken R, Galuppo V, García-moreno LG, Borregan M, Mulder BJM, et al. Heterogeneity of aortic disease severity in patients with Loeys–Dietz syndrome. Heart. 2016;102:626–32.PubMedCrossRef

31.

Jondeau G, Ropers J, Regalado E, Braverman A, Evangelista A, Teixedo G, et al. International registry of patients carrying TGFBR1 or TGFBR2 mutations results of the MAC (Montalcino aortic consortium). Circ Cardiovasc Genet. 2016;9:548–58.PubMedPubMedCentralCrossRef

32.

Isselbacher EM, Preventza O, Hamilton Black J, Augoustides JG, Beck AW, Bolen MA, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease. J Am Coll Cardiol. 2022;80:e223–393.PubMedCrossRef

33.

Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet Part C Semin Med Genet. 2017;175C:8–26.CrossRef

34.

Pepin M, Schwarze U, Superti-Furga A, Byers P. Clinical and genetic features of Ehlers–Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342:673–80.PubMedCrossRef

35.

Frank M, Albuisson J, Ranque B, Golmard L, Mazzella J-MM, Bal-Theoleyre L, et al. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers–Danlos syndrome. Eur J Hum Genet. 2015;23:1657–64.PubMedPubMedCentralCrossRef

36.

Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Adès LC, et al. Clinical validity of genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol. 2018;72:605–15.PubMedPubMedCentralCrossRef

37.

Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA, et al. The spectrum, management and clinical outcome of Ehlers–Danlos syndrome type IV: a 30-year experience. J Vasc Surg. 2005;42:98–106.PubMedCrossRef

38.

Adham S, Legrand A, Bruno RM, Billon C, Dalens V, Boutouyrie P, et al. Assessment of arterial damage in vascular Ehlers–Danlos syndrome: a retrospective multicentric cohort. Front Cardiovasc Med. 2022;9: 953894.PubMedPubMedCentralCrossRef

39.

Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV). Genet Med. 2014;16:881–8.PubMedCrossRef

40.

Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers–Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376:1476–84.PubMedCrossRef

41.

Frank M, Adham S, Seigle S, Legrand A, Mirault T, Henneton P, et al. Vascular Ehlers–Danlos syndrome: long-term observational study. J Am Coll Cardiol. 2019;73:1948–57.PubMedCrossRef

42.

Freeman RK, Swegle J, Sise MJ. The surgical complications of Ehlers–Danlos syndrome. Am Surg. 1996;62:869–73.PubMed

43.

Zilocchi M, Macedo TA, Oderich GS, Vrtiska TJ, Biondetti PR, Stanson AW. Vascular Ehlers–Danlos syndrome: imaging findings. Am J Roentgenol. 2007;189:712–9.CrossRef

44.

Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, et al. Mutations in smooth muscle α-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet. 2007;39:1488–93.PubMedCrossRef

45.

Zhu L, Vranckx R, Van Kien PK, Lalande A, Boisset N, Mathieu F, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006;38:343–9.PubMedCrossRef

46.

Wang L, Guo DC, Cao J, Gong L, Kamm KE, Regalado E, et al. Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet. 2010;87:701–7.PubMedPubMedCentralCrossRef

47.

Mariscalco G, Debiec R, Elefteriades JA, Samani NJ, Murphy GJ. Systematic review of studies that have evaluated screening tests in relatives of patients affected by nonsyndromic thoracic aortic disease. J Am Heart Assoc. 2018;7: e009302.PubMedPubMedCentralCrossRef

48.

Abbasciano RG, Mariscalco G, Barwell J, Owens G, Zakkar M, Joel-David L, et al. Evaluating the feasibility of screening relatives of patients affected by nonsyndromic thoracic aortic diseases: the REST study. J Am Heart Assoc. 2022;11: e023741.PubMedPubMedCentralCrossRef

49.

Regalado ES, Guo DC, Prakash S, Bensend TA, Flynn K, Estrera A, et al. Aortic disease presentation and outcome associated with ACTA2 mutations. Circ Cardiovasc Genet. 2015;8(3):457–64.PubMedPubMedCentralCrossRef

50.

Sherrah AG, Andvik S, van der Linde D, Davies L, Bannon PG, Padang R, et al. Nonsyndromic thoracic aortic aneurysm and dissection outcomes with Marfan syndrome versus bicuspid aortic valve aneurysm. J Am Coll Cardiol. 2016;67:618–26.PubMedCrossRef

51.

Regalado ES, Morris SA, Braverman AC, Hostetler EM, De Backer J, Li R, et al. Comparative risks of initial aortic events associated with genetic thoracic aortic disease. J Am Coll Cardiol. 2022;80:857–69.PubMedCrossRef

52.

Milewicz DM, Østergaard JR, Ala-Kokko LM, Khan N, Grange DK, Mendoza-Londono R, et al. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet Part A. 2010;152 A:2437–43.CrossRef

53.

Isselbacher EM, Bonaca MP, Di Eusanio M, Froehlich J, Bassone E, Sechtem U, et al. Recurrent aortic dissection: observations from the international registry of aortic dissection. Circulation. 2016;134:1013–24.PubMedCrossRef

54.

David TE, David CM, Manlhiot C, Colman J, Crean AM, Bradley T. Outcomes of aortic valve-sparing operations in Marfan syndrome. J Am Coll Cardiol. 2015;66:1445–53.PubMedCrossRef

55.

Finkbohner R, Johnston D, Crawford ES, Coselli J, Milewicz DM. Marfan syndrome: long-term survival and complications after aortic aneurysm repair. Circulation. 1995;91:728–33.PubMedCrossRef

56.

Coselli JS, Volguina IV, LeMaire SA, Connolly HM, Sundt TM, Milewicz DM, et al. Midterm outcomes of aortic root surgery in patients with Marfan syndrome: a prospective, multicenter, comparative study. J Thorac Cardiovasc Surg. 2021;165:1790–9.PubMedCrossRef

57.

den Hartog AW, Franken R, Zwinderman AH, Timmermans J, Scholte AJ, van den Berg MP, et al. The risk for type B aortic dissection in Marfan syndrome. J Am Coll Cardiol. 2015;65:246–54.CrossRef

58.

Curtis SL, Swan L. Aortopathy in pregnancy. Heart. 2022;108:1851–7.PubMedCrossRef

59.

Lopez-Sainz A, Mila L, Rodriguez-Palomares J, Limeres J, Granato C, La Mura L, et al. Aortic branch aneurysms and vascular risk in patients with Marfan syndrome. J Am Coll Cardiol. 2021;77:3005–12.PubMedCrossRef

60.

Henkin S, Negrotto SM, Tweet MS, Kirmani S, Deyle DR, Gulati R, et al. Spontaneous coronary artery dissection and its association with heritable connective tissue disorders. Heart. 2016;102:876–81.PubMedCrossRef

61.

Kaadan MI, MacDonald C, Ponzini F, Duran J, Newell K, Pitler L, et al. Prospective cardiovascular genetics evaluation in spontaneous coronary artery dissection. Circ Genom Precis Med. 2018;11: e001933.PubMedCrossRef

62.

Murad AM, Hill HL, Wang Y, Ghannam M, Yang ML, Pugh NL, et al. Spontaneous coronary artery dissection is infrequent in individuals with heritable thoracic aortic disease despite partially shared genetic susceptibility. Am J Med Genet Part A. 2022;188A:1448–56.CrossRef

63.

Adlam D, Olson TM, Combaret N, Kovacic JC, Iismaa SE, Al-Hussaini A, et al. Association of the PHACTR1/EDN1 genetic locus with spontaneous coronary artery dissection. J Am Coll Cardiol. 2019;73:58–66.PubMedPubMedCentralCrossRef

64.

Saw J, Yang ML, Trinder M, Tcheandjieu C, Xu C, Starovoytov A, et al. Chromosome 1q21.2 and additional loci influence risk of spontaneous coronary artery dissection and myocardial infarction. Nat Commun. 2020;11:4432.ADSPubMedPubMedCentralCrossRef

65.

Tarr I, Hesselson S, Iismaa SE, Rath E, Monger S, Troup M, et al. Exploring the genetic architecture of spontaneous coronary artery dissection using whole-genome sequencing. Circ Genom Precis Med. 2022;15: e003527.PubMedPubMedCentralCrossRef

66.

Debette S, Markus HS. The genetics of cervical artery dissection: a systematic review. Stroke. 2009;40:459–66.CrossRef

67.

Adham S, Billon C, Legrand A, Domigo V, Denarié N, Charpentier E, et al. Spontaneous cervical artery dissection in vascular Ehlers–Danlos syndrome: a cohort study. Stroke. 2021;52:1628–35.PubMedCrossRef

68.

Grond-Ginsbach C, Brandt T, Kloss M, Aksay SS, Lyrer P, Traenka C, et al. Next generation sequencing analysis of patients with familial cervical artery dissection. Eur Stroke J. 2017;2:137–43.PubMedPubMedCentralCrossRef

69.

Morris SA, Orbach DB, Geva T, Singh MN, Gauvreau K, Lacro RV. Increased vertebral artery tortuosity index is associated with adverse outcomes in children and young adults with connective tissue disorders. Circulation. 2011;124:388–96.PubMedCrossRef

70.

Chivulescu M, Krohg-Sørensen K, Scheirlynck E, Lindberg BR, Dejgaard LA, Lie ØH, et al. Mitral annulus disjunction is associated with adverse outcome in Marfan and Loeys–Dietz syndromes. Eur Heart J Cardiovasc Imaging. 2021;22:1035–44.PubMedCrossRef

71.

Eleshra A, Panuccio G, Spanos K, Rohlffs F, von Kodolitsch Y, Kölbel T. Safety and effectiveness of TEVAR in native proximal landing zone 2 for chronic type B aortic dissection in patients with genetic aortic syndrome. J Endovasc Ther. 2022;29:717–23.PubMedCrossRef

72.

Jiang X, Chen B, Jiang J, Shi Y, Ma T, Fu W, et al. Outcomes of endovascular therapy for Stanford type B aortic dissection in patients with Marfan syndrome. J Thorac Cardiovasc Surg. 2023;165:1999–2007.PubMedCrossRef

73.

Kölbel T, Eleshra A, Aldag M, Rohlffs F, Debus SE, Honig S, et al. Endovascular treatment of aortic pathologies in patients with Marfan syndrome: single-center experience. J Endovasc Ther. 2022;29:602–10.PubMedCrossRef

74.

Le HuuA, Olive JK, Cekmecelioglu D, Chatterjee S, Amarasekara HS, Green SY, et al. Endovascular therapy for patients with heritable thoracic aortic disease. Ann Cardiothorac Surg. 2022;11:31–6.CrossRef

75.

Pellenc Q, Girault A, Roussel A, De Blic R, Cerceau P, Raffoul R, et al. Optimising aortic endovascular repair in patients with Marfan syndrome. Eur J Vasc Endovasc Surg. 2020;59:577–85.PubMedCrossRef

76.

Qato K, Conway A, Lu E, Tran NN, Giangola G, Carroccio A. Outcomes of thoracic endovascular aneurysm repair (TEVAR) in patients with connective tissue disorders. Vasc Endovasc Surg. 2020;54:676–80.CrossRef

77.

Steinmetz LM, Coselli JS. Endovascular repair in patients with Marfan syndrome: concerns amid controversy. Ann Vasc Surg. 2023;94:1–7.PubMedCrossRef

78.

Klarin D, Verma SS, Judy R, Dikilitas O, Wolford BN, Paranjpe I, et al. Genetic architecture of abdominal aortic aneurysm in the million veteran program. Circulation. 2020;142:1633–46.PubMedPubMedCentralCrossRef

79.

Pirruccello JP, Chaffin MD, Chou EL, Fleming SJ, Lin H, Nekoui M, et al. Deep learning enables genetic analysis of the human thoracic aorta. Nat Genet. 2022;54:40–51.PubMedCrossRef

80.

Tcheandjieu C, Xiao K, Tejeda H, Lynch JA, Ruotsalainen S, Bellomo T, et al. High heritability of ascending aortic diameter and trans-ancestry prediction of thoracic aortic disease. Nat Genet. 2022;54:772–82.PubMedCrossRef

Titel: Diagnosis and treatment of cardiovascular disease in patients with heritable connective tissue disorders or heritable thoracic aortic diseases
verfasst von: Takeshi Yagyu
Teruo Noguchi
Publikationsdatum: 05.01.2024
Verlag: Springer Nature Singapore
Erschienen in: Cardiovascular Intervention and Therapeutics / Ausgabe 2/2024
Print ISSN: 1868-4300
Elektronische ISSN: 1868-4297
DOI: https://doi.org/10.1007/s12928-023-00977-0

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Diagnosis and treatment of cardiovascular disease in patients with heritable connective tissue disorders or heritable thoracic aortic diseases

Abstract

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Volume–outcome relationships for extracorporeal membrane oxygenation in acute myocardial infarction

Feasibility of contrast-free left atrial appendage closure with WATCHMAN FLX device for patients with chronic kidney disease

IMPELLA® mechanical circulatory support delivery using a VIABAHN VBX-covered stent

Consensus document on the clinical application of invasive functional coronary angiography from the Japanese Association of Cardiovascular Intervention and Therapeutics

Trajectory of pulmonary congestion during TAVR

Impact of stent strut link location in proximal balloon edge dilation technique for bifurcation percutaneous coronary intervention

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie